UNSPSC 51172486: Idursulfase

Idursulfase is a purified form of human iduronate-2-sulfatase, a lysosomal enzyme is used to treat some of the symptoms of a genetic condition called Hunter's syndrome, also called mucopolysaccharidosis.

UNSPSC 51172486 Idursulfase, a Commodity code, shows no relevant recent state and local procurement activity. The source contains seventeen state and local opportunities posted between January and July 2026, but none involves idursulfase or pharmaceutical procurement aligned with this enzyme-replacement therapy used to treat mucopolysaccharidosis II. The opportunities posted under this code number include a county purchasing department relocation notice, a reverse trade show announcement, vendor forums, a nursing staff survey, oxygen cylinder rental, and multi-state pharmaceutical cooperative contracts for generics and OTC products—none of which address idursulfase or specialty biologics procurement at the state or local level.

The mismatch between the code designation and actual buying activity suggests either a data-entry error in the source or that idursulfase procurement through state and local channels is extremely sparse or absent. Bidders evaluating this code should verify the coding assignment with the relevant issuing bodies before committing resources to pursue opportunities. The related MMCAP multi-state pharmaceutical RFP (solicitation S1070000015802, due March 26, 2026) and Pinellas County forensic drug standards procurement (solicitation 260305ITQ, due April 23, 2026) represent the only active pharmaceutical supply contracts in the dataset, neither of which covers specialty biopharmaceuticals like idursulfase.